User loginNavigation |
Emergent BioSolutions moves forward with typhoid vaccine
Emergent BioSolutions is on the path to finding gold with its typhoid vaccine following positive results in a Phase II trial.
The Maryland-based biopharmaceutical company is developing a single-dose oral drinkable typhoid vaccine aimed to take on Crucell’s three to four dose oral formulation and Sanofi’s injectable formulation. The global travellers market was worth $130m (€92m) in 2003, and is expected to increase to $200m by 2014. According to the company, the typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity with an overall immune response rate of greater than 50 per cent, with 95 per cent confidence. “We are very pleased to have met the objective of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine,” Emergent BioSolutions chairman and chief executive Fuad El-Hibri said. Related posts:
Related posts brought to you by Yet Another Related Posts Plugin.
Submitted by admin on Fri, 08/14/2009 - 05:10.
|
Category CloudTag CloudWho's new
Who's onlineThere are currently 0 users and 1 guest online.
Recent comments
|
70-633 practice
UGG boots are popular among
Some replica watches store
well,the following i will do
Dresses, evening, cocktail,
Microsoft Office 2007 Office
WOW first time single-dose
WOW first time single-dose drinkable typhoid vaccine. This sounds very much exciting and convenient for the patients too. This will indeed help the patient to have speedy recovery. I wish all the best for this project.MNUI
Post new comment